Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Current Signal: SELL (auto-tracking)
-1.90% $88.88
America/New_York / 24 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 2 907.74 mill |
EPS: | -0.770 |
P/E: | -115.43 |
Earnings Date: | Apr 28, 2024 |
SharesOutstanding: | 32.72 mill |
Avg Daily Volume: | 0.740 mill |
RATING 2024-04-24 |
---|
A+ |
Strong Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Sell | |
Return On Equity: | Buy | |
Return On Asset: | Buy | |
DE: | Strong Buy | |
P/E: | Strong Buy | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -115.43 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.52x |
Company: PE -115.43 | industry: PE 222.16 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 84.22 - 93.54 ( +/- 5.24%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-17 | Hassanein Waleed H | Sell | 4 000 | Stock Option (Right to Buy) |
2024-04-17 | Hassanein Waleed H | Buy | 4 000 | Common Stock |
2024-04-17 | Hassanein Waleed H | Sell | 4 000 | Common Stock |
2024-04-10 | Hassanein Waleed H | Sell | 12 000 | Stock Option (Right to Buy) |
2024-04-10 | Hassanein Waleed H | Buy | 12 000 | Common Stock |
INSIDER POWER |
---|
2.74 |
Last 100 transactions |
Buy: 325 751 | Sell: 307 375 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $88.88 (-1.90% ) |
Volume | 0.538 mill |
Avg. Vol. | 0.740 mill |
% of Avg. Vol | 72.66 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $88.73 | N/A | Active |
---|
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.